{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:09:29Z","timestamp":1785881369977,"version":"3.56.0"},"reference-count":8,"publisher":"Baskent University","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.6002\/ect.2024.0034","type":"journal-issue","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T02:13:34Z","timestamp":1714011214000},"source":"Crossref","is-referenced-by-count":1,"title":[],"prefix":"10.6002","volume":"22","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Trotter PB, Summers DM, Ushiro-Lumb I, et al. Use of organs from hepatitis C virus-positive donors for uninfected recipients: a potential cost-effective approach to save lives? Transplantation. 2018;102(4):664-672. doi:10.1097\/TP.0000000000002033.","DOI":"10.1097\/TP.0000000000002033"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353-1363. doi:10.1002\/hep.27978","DOI":"10.1002\/hep.27978"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;376(24):2394-2395. doi:10.1056\/NEJMc1705221","DOI":"10.1056\/NEJMc1705221"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Reese PP, Abt PL, Blumberg EA, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169(5):273-281. doi:10.7326\/M18-0749","DOI":"10.7326\/M18-0749"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168(8):533-540. doi:10.7326\/M17-2871","DOI":"10.7326\/M17-2871"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Sise ME, Goldberg DS, Kort JJ, et al. Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol. 2020;31(11):2678-2687. doi:10.1681\/ASN.2020050686","DOI":"10.1681\/ASN.2020050686"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Sise ME, Goldberg DS, Schaubel DE, et al. One-year outcomes of the multi-center study to transplant hepatitis C-infected kidneys (MYTHIC) trial. Kidney Int Rep. 2022;7(2):241-250. doi:10.1016\/j.ekir.2021.11.022","DOI":"10.1016\/j.ekir.2021.11.022"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Jandovitz N, Nair V, Grodstein E, et al. Hepatitis C-positive donor to negative recipient kidney transplantation: a real-world experience. Transpl Infect Dis. 2021;23(3):e13540. doi:10.1111\/tid.13540","DOI":"10.1111\/tid.13540"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T03:44:50Z","timestamp":1714362290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2024\/22\/3\/0\/185\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2024.0034","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}